Recent and Upcoming Drug Therapies for Pediatric Heart Failure.

Front Pediatr · 2021 · PMC8632454 · PMID 34858897

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

There was a highly significant 18% relative risk reduction for death from cardiovascular causes or hospitalization for heart failure, by sacubitril/valsartan compared with enalapril.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.